Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia.
The authors examined the efficacy of 2-chlorodeoxyadenosine (2-CDA) in the treatment of refractory inhibitors to factor VIII in persons without hemophilia. The drug was administered to 6 patients at a dose of 0.1 mg/kg as a 24-hour continuous infusion for a total of 7 days each cycle. An average of 3 immunosuppressive regimens per patient had been administered prior to enrollment in this study. The median inhibitor titer against human and porcine factor VIII before treatment with 2-CDA was 31 Bethesda units (BUs) and 9 BU, respectively. The median inhibitor titer against human and porcine factor VIII after treatment was 3.5 BU and 1.5 BU, respectively. The median time to reach nadir inhibitor titer in this study was 137 days, whereas the median time to reach a 50% increase in factor VIII was 117 days. No major toxicity was observed in any patient in this study. Patients with acquired inhibitors to factor VIII refractory to conventional immunosuppressive therapy may respond favorably to 2-CDA.
Sallah
Sabah
S
Thrombosis and Hemostasis Program and Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport 71130, USA. asalla@lsuhsc.edu
Wan
Jim Y
JY
D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000097:blood / Q000150:complications / Q000209:etiology; D017338:Cladribine / Q000008:administration & dosage* / Q000633:toxicity; D005169:Factor VIII / Q000276:immunology*; D005260:Female; D006470:Hemorrhage / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D017338:Cladribine; D005169:Factor VIII